30 closest matches · ranked by relevance
Herpes Zoster
Primary: Frequencies of Glycoprotein E (gE)-Specific Cluster of Differentiation 4 (CD4) / CD8 T Cells With at Least Two Antigen-specific Cytokines: Interferon Gamma (IFN-γ)…
Healthy Participants
Primary: Percentage of Total Radiocarbon (14C) Excreted in Urine — 11.9; 20.7 Percentage of 14C in urine
Healthy Participants
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 1; 2; 1; 2 Participants
Healthy Participants
Primary: Cohort 1: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 5; 8; 6; 8 Participants
Genetic Disease · Nonsense Mutation
Primary: Pharmacokinetic Parameters - Plasma AUC0-24 — 1105.126; 3125.484; 11018.22; 28235.823 ng*h/mL
Atopic Dermatitis
Primary: Number of Participants With Treatment-Emergent Adverse Events — 205; 223; 14; 17 Participants
Meningococcal Disease
Primary: 1. Percentages of Subjects With HT-hSBA (High-throughput Human Serum Bactericidal Assay) Seroresponse Against N. Meningitidis Serogroups A, C, W and Y. — 96; 94; 85; 100…
Smoking Cessation
Primary: Expired-air CO Verified Point-prevalence Abstinence — 44; 42 participants
Coronary Heart Disease
Primary: Percent Change From Baseline in HDL-C — 33.76; 3.69 Percentage Change of HDL-C
Infections, Meningococcal
Primary: Number of Seroprotected Subjects Against the Vaccine Meningococcal Serogroups — 404; 132; 404; 131 Subjects
Respiratory Syncytial Virus Infections
Primary: Number of Participants With Any Solicited Administration Site Adverse Events (AEs) — 1; 6; 5; 21 Participants
Respiratory Syncytial Viruses
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) — 6; 7; 4; 9 Participants
Safety Issues
Primary: Characterize the Safety and Tolerability of EXT608 — 2; 2; 0; 0 Participants
Healthy Participants
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 1; 2; 3; 2 Participants
Healthy Volunteers · Adult · Pharmacokinetics
Primary: Area Under the Plasma Concentration-Time Profile From Time Zero Extrapolated to Infinite Time (AUCinf) of Ritlecitinib — 389.1; 398.3; 378.0; 387.8 nanogram*hour per…
Type1diabetes
Primary: Percentage of Time Spent With Dexcom CGMG < 60 mg/dl — 1.32; 1.95; 1.05; 0.99 percentage of time
Diabetes Mellitus, Type 2
Primary: Number of Enrollments in the Study Over One Year — 4; 2 Participants
Lyme Borreliosis
Primary: GMTs for IgG Against Each OspA Serotype — 278.5; 274.7; 21.0; 545.2 Units per milliliter (U/mL)
Sarcopenia
Primary: Population I: Short Physical Performance Battery (SPPB) Total Score at Week 49 — 8.8; 10.2; 8.0; 8.0 Scores on a scale — p=0.759
Hepatitis A · Hepatitis B
Primary: Number of Subjects With Anamnestic Response to the Challenge Dose for Anti-hepatitis A (Anti-HAV) Antibodies — 164; 164; 162 Participants
Attention Deficit Disorder With Hyperactivity
Primary: Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 8; 126; 0 participants
Meningococcal Disease
Primary: Persistence of Geometric Mean Antibody Titers in Children (Who Previously Received 4 Doses of Men B Vaccine), at 40 Months of Age. — 3.24; 5.34; 4.25; 5.11 Titers
Diabetes Mellitus, Type 1 · Overweight and Obesity
Primary: Change in Weight - Randomization 1 — -1.6; -1.8; -1.5 kilograms — p=0.98
Meningococcal Disease
Primary: Persistence of Serum Bactericidal Antibody Titers in Children (at 40 Months of Age), Twenty-eight Months After Completing Primary Vaccination. — 1.26; 2.55; 1.08; 41…
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Subjects With hSBA Titers ≥1:4 Against Meningococcal Strains, At 18 Months After Month-6 Vaccination in V72P10 Study, and in Naive Subjects. — 31; 40; 40…
Opioid Use Disorder (OUD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) — 8; 6; 6; 9 Participants
Healthy
Primary: Change in Intact FGF23 — 1.001; 1.006; 1.009; 1.005 pg/ml — p=0.3738
Chikungunya Virus Infection
Primary: Frequency of Adverse Events (AEs) — 5; 3; 2; 3 Participants
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical…
Neovascular Age-related Macular Degeneration
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 3; 2; 1 Participants